Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.

Do analysts prefer CORT or RPRX?

Corcept Therapeutics currently has a consensus target price of $143.25, suggesting a potential upside of 98.71%. Royalty Pharma has a consensus target price of $42.50, suggesting a potential upside of 29.73%. Given Corcept Therapeutics' higher possible upside, equities analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media refer more to CORT or RPRX?

In the previous week, Royalty Pharma had 3 more articles in the media than Corcept Therapeutics. MarketBeat recorded 15 mentions for Royalty Pharma and 12 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.28 beat Royalty Pharma's score of 1.28 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, CORT or RPRX?

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$675.04M	11.27	$106.14M	$1.24	58.14
Royalty Pharma	$2.26B	8.34	$858.98M	$1.45	22.59

Is CORT or RPRX more profitable?

Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	22.35%	24.54%	20.24%
Royalty Pharma	37.94%	24.40%	14.01%

Which has more risk & volatility, CORT or RPRX?

Corcept Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Does the MarketBeat Community believe in CORT or RPRX?

Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.37% of users gave Corcept Therapeutics an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Corcept Therapeutics	Outperform Votes 546 71.37%	Underperform Votes 219 28.63%
Royalty Pharma	Outperform Votes 325 67.99%	Underperform Votes 153 32.01%

Do institutionals and insiders believe in CORT or RPRX?

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by company insiders. Comparatively, 18.9% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Corcept Therapeutics beats Royalty Pharma on 11 of the 18 factors compared between the two stocks.